EVT-101
- Generic Name
- EVT-101
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15Cl2F3N4
- CAS Number
- 1189088-41-2
- Unique Ingredient Identifier
- B55T45AA8F
- Indication
Investigated for use/treatment in alzheimer's disease, neurologic disorders, pain (acute or chronic), and parkinson's disease.
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01128452
- Locations
- 🇺🇸
Evotec Study Site 1, Baltimore, Maryland, United States
🇺🇸Evotec Study Site 12, Houston, Texas, United States
🇺🇸Evotec Study Site 2, Oak Brook, Illinois, United States
The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2008-02-18
- Lead Sponsor
- Evotec Neurosciences GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT00526968
- Locations
- 🇬🇧
Centre for Neuroimaging Science, Box 089, Institute of Psychiatry, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath